Walleye Capital’s NovoCure NVCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-1,535
Closed -$23.3K – 6123
2026
Q2
$23.3K Buy
+1,535
New +$23.2K ﹤0.01% 4358
2026
Q1
– Sell
-11,676
Closed -$151K – 4794
2025
Q4
$151K Sell
11,676
-205,117
-95% -$2.63M ﹤0.01% 3679
2025
Q3
$2.8M Buy
216,793
+204,975
+1,734% +$2.74M 0.01% 1336
2025
Q2
$210K Buy
+11,818
New +$206K ﹤0.01% 3324
2025
Q1
– Sell
-23,878
Closed -$712K – 4853
2024
Q4
$712K Buy
23,878
+21,961
+1,146% +$465K ﹤0.01% 2684
2024
Q3
$30K Sell
1,917
-8,281
-81% -$150K ﹤0.01% 4742
2024
Q2
$175K Sell
10,198
-41,502
-80% -$730K ﹤0.01% 4401
2024
Q1
$808K Sell
51,700
-60,383
-54% -$888K ﹤0.01% 2786
2023
Q4
$1.67M Sell
112,083
-23,564
-17% -$315K ﹤0.01% 1925
2023
Q3
$2.19M Buy
135,647
+95,647
+239% +$2.76M 0.01% 1670
2023
Q2
$1.66M Buy
+40,000
New +$2.48M 0.01% 1457
2023
Q1
– Sell
-7,308
Closed -$584K – 4238
2022
Q4
$536K Buy
+7,308
New +$550K 0.01% 1406
2022
Q3
– Sell
-2,972
Closed -$232K – 3438
2022
Q2
$207K Buy
+2,972
New +$224K 0.01% 1507
2020
Q4
– Sell
-2,128
Closed -$237K – 1055
2020
Q3
$237K Buy
+2,128
New +$170K 0.03% 564
2019
Q4
– Sell
-8,204
Closed -$613K – 2115
2019
Q3
$613K Sell
8,204
-1,529
-16% -$122K 0.04% 654
2019
Q2
$615K Buy
9,733
+8,223
+545% +$417K 0.07% 418
2019
Q1
$73K Buy
+1,510
New +$72.7K 0.01% 1119

Other funds holding NVCR

Walleye Capital's NVCR Position: Q3 2026 in Review

Walleye Capital sold out of NovoCure (NVCR) in Q3 2026, closing a stake of 1,535 shares — an estimated $23.3K sold.

Walleye Capital first reported a position in NVCR in Q1 2019 and held it in 17 quarters. The position peaked at $2.8M in Q3 2025. 242 funds tracked by Wall St. Rank hold NVCR as of Q3 2026.

  • Walleye Capital reported no remaining NovoCure position as of Q3 2026 after selling out during the quarter.
  • Walleye Capital sold 1,535 NovoCure shares in Q3 2026, an estimated $23.3K.
  • Walleye Capital first reported a position in NovoCure in Q1 2019 and held it in 17 quarters.
  • Walleye Capital's NovoCure position peaked at $2.8M in Q3 2025.
  • 242 funds tracked by Wall St. Rank held NovoCure as of Q3 2026.

Based on Walleye Capital's 13F filing for Q3 2026, filed 13 Nov 2026.